Privi Speci. Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Published 25 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹13.6K Cr
The company targets achieving Rs. Privi Speciality Chemicals aims for a revenue target of Rs.
From Privi Speci.'s Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Price
₹3,430
Market Cap
₹13.6K Cr
P/E Ratio
38.9
Revenue Rank
Margin Rank
How does Privi Speci. rank in Chemicals & Petrochemicals?
Compare Privi Speci. against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.
Privi Speci. — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹722 Cr, net profit ₹94 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 2- →The company targets achieving Rs. 5,000 crore in revenue and over Rs. 1,000 crore in EBITDA within the next 3-4 years, representing approximately 2x growth.
- →They expect a 20% CAGR in revenue while maintaining similar EBITDA margins.
- →Capacity expansions from 48,000 metric tons to 66,000 metric tons by September 2027 will support growth.
- →New specialty molecules including those based on furfural (from corn cob) will add about Rs. 1,000 crore+ to revenue.
- →The company’s JV PRIGIV is expected to contribute meaningfully and scale further.
- →Operational efficiencies and improved product mix are expected to sustain margins near 25%.
- →Growth is driven by volume increases, price rises, and product mix improvements.
- →The bio-based pilot plant and other breakthrough technologies may contribute to future growth beyond the current 5K, 1K plan.
📈 Profitability & Margins
Rank 3- →Privi Speciality Chemicals aims for a revenue target of Rs. 5,000 crore and EBITDA exceeding Rs. 1,000 crore within the next 3-4 years, reflecting about 2x growth.
- →The company targets sustaining EBITDA margins around 24.6% to 25%, supported by operational efficiencies, cost optimization, and improved product mix.
- →Management is confident in maintaining a 20% CAGR over the medium term with similar EBITDA margins.
- →Profit after tax showed robust growth with Rs. 83.2 crore in Q1 FY27 vs. Rs. 61.46 crore in Q1 FY26.
- →Capex of Rs. 850-900 crore planned over the next two years will support Phase-2 and Phase-3 expansions, driving future earnings.
- →Continuous chemistry adoption and new specialty molecules (like Maltol, Ethyl Maltol, Musk T, and furfural-based products) are expected to contribute meaningfully by H2 FY27 onwards.
- →Focus on internal accrual funding with prudent debt levels ensures financial flexibility to support growth.
🏗️ Capital Expenditure Plans
Yes- →Ongoing Phase-1 CAPEX to expand production capacity from 48,000 to 54,000 metric tons, expected to be commercialized by September 2026.
- →Planned Phase-2 and Phase-3 CAPEX for multi-specialty aroma chemicals project, targeting capacity expansion to 66,000 metric tons by September 2027.
- →Total CAPEX for FY26–FY28 estimated at around Rs. 850 to 900 crores to complete Phase-2 and Phase-3.
- →Rs. 300 crore CAPEX for existing products slightly delayed, now expected September 2026.
- →Additional Rs. 300 crore CAPEX each for new specialty products including Maltol and Musk T.
- →Joint Venture PRIGIV expanding with an additional Rs. 50 crore equity investment for next-phase expansion.
- →Future demonstration biomass plant (2 tons/day) planned post 5K, 1K plan for pilot testing breakthrough technologies; commercialization expected after 12-15 months of pilot runtime.
- →CAPEX funded mainly through internal accruals with possible bank borrowings, maintaining strong debt-to-equity and debt-to-EBITDA ratios.
💰 Fundraising & Capital Structure
Yes- →Phase-2 CAPEX has commenced; Phase-3 expected around end of this year or early next year.
- →Funding for these phases will primarily come from internal accruals.
- →If needed, borrowing from banks or financial institutions at competitive rates may be considered.
- →Debt-to-EBITDA and debt-to-equity ratios will be closely monitored and maintained well below preferred thresholds.
- →No specific mention of any equity fundraising in the current/future plans.
- →The company maintains a prudent capital structure with a net debt-to-equity ratio of 0.57x as of June 2026, reflecting financial discipline.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Privi Speci. Q1 FY27 results?
The company targets achieving Rs. Privi Speciality Chemicals aims for a revenue target of Rs.
What is Privi Speci. share price analysis?
Privi Speci. currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 38.9 with a market cap of ₹13,593 Cr. Investors should review the full earnings analysis for detailed insights.
Is Privi Speci. planning capital expenditure?
Ongoing Phase-1 CAPEX to expand production capacity from 48,000 to 54,000 metric tons, expected to be commercialized by September 2026.
Keep Privi Speci. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.